CytoDyn Inc. (CYDY: OTCQB) | ASM Microbe 2019 Conference Grants Both Poster and Oral Presentations to CytoDyn for its Pivotal Study of Leronlimab (PRO 140) which Demonstrated Superior Efficacy and Safety in Heavily Treatment-Experienced HIV Patients
(0)
(0)